Your browser doesn't support javascript.
loading
A big step for MYC-targeted therapies.
Atibalentja, Danielle F; Deutzmann, Anja; Felsher, Dean W.
Afiliação
  • Atibalentja DF; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
  • Deutzmann A; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
  • Felsher DW; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA; Department of Pathology, Stanford University, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA. Electronic address: dfelsher@stanford.edu.
Trends Cancer ; 10(5): 383-385, 2024 May.
Article em En | MEDLINE | ID: mdl-38580534
ABSTRACT
The MYC proto-oncogene encodes a master transcriptional regulator that is frequently dysregulated in human cancer. Decades of efforts have failed to identify a MYC-targeted therapeutic, and this is still considered to be a holy grail in drug development. We highlight a recent report by Garralda et al. of a Phase 1 clinical trial of OMO-103 in patients with solid malignancies.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas c-myc / Terapia de Alvo Molecular / Proto-Oncogene Mas / Neoplasias Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas c-myc / Terapia de Alvo Molecular / Proto-Oncogene Mas / Neoplasias Idioma: En Ano de publicação: 2024 Tipo de documento: Article